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SBackground: Pulmonary metastasectomy has become a standard approach for sarcoma, but uncertainty remains
regarding risk factors that accurately assess postoperative prognosis and can be used to guide surgical decision
making.
Methods: We identified 145 patients who underwent 204 consecutive pulmonary metastasectomies for
sarcoma between 1996 and 2009, and examined 174 complete resections in 118 patients. Predictors included
surgical procedure, number/size of lesions, repeat resection, intervals to metastasis and to recurrence,
chemotherapy, sarcoma subtype, distribution of pulmonary and extrapulmonary metastasis, and patient age/sex.
Survival estimates were based on Kaplan-Meier analysis and compared using a log-rank test. Predictors were
compared using univariate and multivariate Cox proportional hazards modeling.
Results: Among patients undergoing R0 resections, median survival was 35 months (95% confidence
interval, 22-60 months), with 3-, 5- and 10-year survival of 48%, 42%, and 31%, respectively. The number
or size of lesions did not influence survival. Metastasis synchronous to the primary tumor, but not disease-free
interval, was a significant predictor of worse survival on single variable and adjusted modeling (hazard ratio,
3.0; 95% confidence interval, 1.4-6.6; P ¼ .005); the presence of extrapulmonary metastasis and a need for
anatomic resection were also likely predictors (P ¼ .06 and P ¼ .07). Recurrence of pulmonary metastasis
was not associated with a reduction in survival if completely resected, and a more aggressive and less invasive
surgical approach during the later half of the study period was not associated with a significant decline in
survival.
Conclusions: Evolving surgical practice may allow an increasingly aggressive approach to pulmonary sarcoma
metastasis, which may be facilitated by increased use of a minimally invasive approach. (J Thorac Cardiovasc
Surg 2014;147:1193-201)Approximately 20% to 40% of patients with sarcoma
develop pulmonary metastases.1-4 Unlike many epithelial
cancers, sarcomas very often spread only to the lungs.4-7
Aggressive surgical management of pulmonary metastasis
in sarcoma, including repeat metastasectomy for recurrent
disease, has achieved 5-year survival of 30% or more
in various series.8-11 In 1997, Pastorino and colleagues12
published an analysis of 5206 pulmonary metastasec-
tomies spanning a 50-year period, including 2173 cases
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The Journal of Thoracic and Cardisease-free interval (DFI) before metastasis<36 months,
and single metastasis as independent predictors of survival.
Several groups have since published series of sarcoma
metastasectomies, generally ranging from 50 to 100
patients. Conflicting conclusions have been reached
regarding the significance of DFI, number of lesions, size
of lesions, presence of bilateral disease, and need for repeat
resection.1,2,5,7,13-15
The younger age of sarcoma patients and the increased
likelihood of isolated pulmonary involvement provide a
rationale for an aggressive approach. Updated information
regarding relevant risk factors is critical to optimize
therapeutic decision making. The evolving use of
minimally invasive techniques that may facilitate repeat
operations and reduce recovery times may be of particular
benefit if their application does not affect the efficacy of
more conventional, open approaches.5,16,17 We examined
the outcomes and potential clinical risk factors of patients
undergoing pulmonary metastasectomy for sarcoma over
a 14-year period, with particular regard to an increasing
trend toward a more aggressive, inclusive approach coupled
with an increasing use of minimally invasive technique.diovascular Surgery c Volume 147, Number 4 1193
Abbreviations and Acronyms
DFI ¼ disease-free interval
VATS ¼ video-assisted thoracic surgery
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SMETHODS
Procedures
We identified 204 consecutive pulmonary metastasectomies for
sarcoma conducted in 145 unique patients at our institution between
1996 and 2009 through review of pathology and clinical databases. Patients
were categorized as having undergone either video-assisted thoracoscopic
surgery (VATS) or an open approach (via thoracotomy or sternotomy);
3 procedures converted from VATS to thoracotomy due to adhesions or
difficulty of lesion dissection were considered thoracotomies. Single and
multiple wedge resections and segmentectomies were compared with
anatomic lobectomies, pneumonectomies, and combinations of lobectomy
and wedge resection; these 2 categories of procedures were also
compared with cases requiring en bloc resections of the chest wall or
mediastinal structures. Twelve patients underwent planned staged bilateral
metastasectomies that were conducted within 3 months of each other; for
the purpose of our analyses these 2 operations were considered a single
staged procedure, yielding a total of 162 R0 procedures. Patients were
also divided into an early group undergoing initial resection between
1996 and 2002, and a late group encompassing resections between 2003
and 2009. Approval for this study was obtained from the University of
California, San Francisco Committee on Human Research; consent for
patient participation was waived.
Statistical Analysis
Demographic group comparisons of continuous variables were
performed using the Mann-Whitney U test, and categorical variables
were compared using either c2 or Fisher exact tests.
Survival analysis was the primary statistical approach. Survival time
was calculated as the time to death from either initial metastasectomy or
repeat metastasectomy. Date of death was determined using medical
records or the Social Security Death Master File; vital status was thus
available for every patient undergoing R0 resection. Estimated
survival curves were constructed using the Kaplan-Meier estimator. Raw
(unadjusted) group comparisons of Kaplan-Meier curves were performed
using the log-rank test (or the Wilcoxon test when there appeared to be
nonproportional hazards between groups).
Cox proportional hazards modeling was used to perform both single-
and multiple-predictor analysis. Predictors included DFI, number and
size of lesions, surgical approach and procedure, sarcoma subtype
and grade of primary tumor, metastasis synchronous to primary tumor,
extrapulmonary metastasis, number of lobes involved and bilateral
metastasis, use of chemotherapy, age, sex, and ethnicity. In addition, we
examined the recurrence of pulmonary metastasis, which was designated
to be either resectable or unresectable based on the surgeon’s evaluation
at the time of recurrence, as well as the time to recurrence and the
number of any repeat resections. If there was any indication of non-
proportional hazards in the single-predictor models, we used the Wilcoxon
test comparison of survival, which is robust to departures from the
proportional hazards assumption (continuous variables were first split
into appropriate categories).
Multiple-predictor models were generated using an a priori defined
variable selection procedure based on criteria of statistical significance
and clinical knowledge. The starting multiple-predictor model included a
baseline set of predictor variables (the size and number of lesions and
DFI) selected based on their historical significance in assessing risk after1194 The Journal of Thoracic and Cardiovascular Surpulmonary metastasectomy. Subsequently, a stepwise forward selection
procedure was implemented to determine which of a set of additional
primary predictor variables (ie, extrapulmonary metastasis, surgical
approach, sarcoma subtype, laterality of disease and number of involved
lobes, age, chemotherapy, and histologic grade) was to be included in a
final model. The criterion for predictor retention was P<.1; whenever a
predictor was added, the variable with the highest P value in the current
model was dropped and the model refit in turn until all P values in the
model were< .1. Finally, a set of secondary predictors was considered
such that each was added as a single additional predictor in turn to the final
model based on the baseline and retained primary set of predictors.
These secondary variables were not considered part of the full
step-forward selection procedure to avoid the model becoming overfitted
with too many variables. Instead we examined if each of the secondary
variables added explanatory value in turn. The number of missing data
points was limited; missing data were treated as missing at random, and
patients were excluded from multivariate analysis if 1 covariate was
missing from a particular model being tested.
Although we examined many potential effects, we report nominal
P values, without adjustment for multiple testing. Such adjustment would
be focused on avoidance of 1 or more results with P<.05 in the case where
all differences are truly 0,18-20 which is an extremely unrealistic hypothesis
about the state of nature in our situation. We therefore relied on scientific
judgment rather than formal adjustment methods to indicate where
caution was warranted despite findings with P < .05. In addition,
adjustment would require that each result detract from the others, but
there are clear biologic relationships among many of the issues that we
examine, and these permit coherent sets of findings to reinforce each
other rather than detract from 1 another.21RESULTS
Patients
Of 145 patients identified, 118 underwent 162 procedures
(either unilateral, bilateral, or staged bilateral) involving
complete R0 resection of their metastatic disease. Most of
the patients who did not receive R0 resections (22 out of
27; 82%) were believed, based on preoperative studies,
not to be candidates for attempt at curative resection,
and instead underwent either diagnostic or palliative
procedures. The remaining 5 patients were found at
operation to have more disease than suggested by
preoperative workup, and were deemed unresectable
intraoperatively. Although these interventions can add an
important component to the management of these patients,
they are not intended to prolong survival or delay
recurrence/reintervention, the key end points of our study.
We therefore focused our analyses on factors that may
contribute to decision making in the evaluation of patients
who are candidates for an aggressive surgical approach
directed at possible cure.
The characteristics of patients with R0 resections
are summarized in Table 1. The mean age at initial
metastasectomy was 46.5  15 years. Sixty-two were
men (52.5%). Sarcomas included leiomyosarcoma
(25%), osteosarcoma (16%), synovial sarcoma (14%),
pleomorphic undifferentiated sarcoma (12%), liposarcoma
(5%), chondrosarcoma (5%), spindle cell sarcoma (5%),
and others (18%). Median and mean DFI were 14.3 andgery c April 2014
TABLE 1. Characteristics of patients undergoing complete (R0)
resection (118 out of 145 total patients)
Characteristic Result
Age
Mean  standard deviation (y) 46.5  15.4
Sex
Male 62 (52%)
Female 56 (48%)
Disease-free interval
Mean  standard deviation (y) 2.53  3.28
Distribution of disease
Unilateral 66 (55.9%)
Bilateral 52 (44.1%)
No. of lesions
1 40 (33.9%)
2 21 (17.8%)
3 17 (14.4%)
4þ 39 (33.1%)
Size of largest lesion (cm)
0-3 74 (62.7%)
3-5 20 (16.9%)
>5 24 (20.3%)
Extrapulmonary disease
Yes 11 (9.3%)
No 107 (90.7%)
Chemotherapy
Yes 91 (77.1%)
No 27 (22.9%)
Surgical approach
Video-assisted thoracic surgery 44 (37.3%)
Thoracotomy 67 (56.8%)
Mixed 7 (5.9%)
Surgical procedure
Wedge 82 (69.5%)
Anatomic resection 26 (22%)
En bloc 10 (8.5%)
Histology
Pleomorphic unspecified sarcoma 14 (12%)
Fibrosarcoma 4 (3%)
Osteosarcoma 19 (16%)
Ewing’s sarcoma 5 (4%)
Synovial sarcoma 16 (14%)
Spindle cell sarcoma 6 (5%)
Leiomyosarcoma 29 (24%)
Peripheral nerve sheath 3 (3%)
Chondrosarcoma 6 (5%)
Rhabdomyosarcoma 2 (2%)
Liposarcoma 6 (5%)
Giant cell sarcoma 3 (3%)
Other 5 (4%)
Synchronous metastasis
Yes 15 (12.7%)
No 103 (87.3%)
Repeat resections
0 86 (72.9%)
1 20 (16.9%)
2þ 12 (10.2%)
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S30.4  39.4 months, respectively; 4 DFIs 10 years were
observed. Thirty-seven percent of patients underwent
VATS, and 5.9% had VATS on 1 side with open
thoracotomy on the other. The biggest lesion resected was
between 0 and 3 cm in 62.7%, and>5 cm in 20.4%. The
population was divided evenly between patients with a
single lesion on preoperative imaging (34%), 2 to 3
nodules (33%), and 4 lesions (33%). Forty-one
percent of patients had bilateral disease. Either anatomic
-lobectomy, pneumonectomy, or en bloc resection of
adjacent structures was required in 30.5% of patients,
and extrapulmonary metastasis was encountered at the
time of initial pulmonary metastasectomy in 9.3% of
patients.
Survival
One death was observed within 30 days of operation.
Of 27 patients who underwent incomplete (R1/R2)
resection, follow-up was obtained on 21 patients, 20 of
whom had died by the end of the study period with mean
and median survivals of approximately 12 months. Median
survival for patients undergoing at least 1 complete (R0)
resection of their pulmonary metastasis was 35 months
(95% confidence interval [CI], 23-61); 3-, 5-, and 10-year
survival was estimated to be 48%, 42%, and 31%,
respectively (Figure 1, A). Despite the large number of
predictors examined, only pulmonary metastasis synchro-
nous to the primary tumor was found to be a statistically
significant predictor of higher mortality on univariate
analysis, with a hazard ratio (HR) of 2.7 (95% CI,
1.5-5.1; P ¼ .001). The presence of extrapulmonary
metastasis and the need for anatomic resection were identi-
fied to have HRs of 2.0 (95% CI, 0.97-4.2; P ¼ .06) and
1.6 (95% CI, 0.95-2.8; P ¼ .07), respectively. Categorical
analysis of the size of the largest resected lesion indicated
that lesions 3 to 5 cm were associated with a worse
prognosis than either smaller or larger lesions (HR, 2.0 vs
biggest lesion <3 cm; 95% CI, 1.1-3.6; P ¼ .02); this
observation may have been influenced by the fact that
only 19 patients fell into this subcategory. Our final multiple
predictor model indicated that after adjustment for other
variables, synchronous metastasis and anatomic resection
were the only statistically significant independent
predictors of survival, associated with HRs of 3.0 (95%
CI, 1.4-6.6; P ¼ .005) and 2.6 (95% CI, 1.3-4.9;
P ¼ .004), respectively (Table 2).
Despite the strong association of synchronous metastasis
with a poor outcome, DFI was a weaker predictor of
survival, considered either as a continuous variable
(HR, 0.95; 95% CI, 0.88-1.03; P ¼ .21) or categorical
variable (Table 2). The indication of nonproportional
hazards with this predictor led us to examine Kaplan-
Meier survival curves for DFIs of<1 year, 1 to 2 years,diovascular Surgery c Volume 147, Number 4 1195
FIGURE 1. A, Overall survival from the time of initial metastasectomy
among patients with complete R0 resection (n ¼ 118). B, Overall survival in
patients with disease-free interval (DFI) before metastasis of either<1 year
(black, n ¼ 49), 1 to 2 years (blue, n ¼ 25), or>2 years (green, n ¼ 42).
C, Overall survival in patients with (black, n ¼ 11) or without (blue,
n¼ 107) extrapulmonarymetastasis at the time of pulmonarymetastasectomy.
TABLE 2. Cox single predictor and adjusted proportional hazards
modeling
Model
Hazard ratio
(95% confidence interval)
P
value
Single predictor model
Metastasis synchronous to primary 2.70 (1.50-5.10) .001
Extrapulmonary metastasis 2.00 (0.97-4.20) .06
Need for anatomic resection 1.62 (0.95-2.80) .07
Disease-free interval 1-2 y* 0.78 (0.43-1.48) .47
Disease-free interval>2 y* 0.72 (0.43-1.20) .20
No. of lesions 1.02 (0.98-1.07) .37
Bilateral disease 1.13 (0.71-1.79) .61
Size of largest lesion 0.99 (0.94-1.05) .82
Multiple predictor model
Metastasis synchronous to primary 3.00 (1.40-6.60) .005
Need for anatomic resection 2.60 (1.34-4.90) .004
Extrapulmonary metastasis 1.84 (0.84-4.00) .13
Disease-free interval 1-2 y* 1.04 (0.50-2.10) .92
Disease-free interval>2 y* 0.90 (0.49-1.67) .74
No. of lesions 0.99 (0.94-1.05) .83
*Compared with disease-free interval<1 y.
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Sand >2 years (Figure 1, B); this analysis suggests
that survival may be somewhat better during the first 3 years
after metastasectomy for DFI>2 years, but that longer-term
survival in this group subsequently drops down
to levels seen in patients who had had a more rapid
progression to metastatic disease. Similarly, extra-
pulmonary metastasis violated the proportional hazards
assumption; Kaplan-Meier analysis indicated that these
patients succumbed quickly to their disease, with 2-year
survival estimated at just 27.3% (Figure 1, C).1196 The Journal of Thoracic and Cardiovascular SurThe majority of patients undergoing R0 metastasectomy
received chemotherapy; 17% during the initial treatment of
their primary sarcoma only, and 60% as an adjuvant to
metastasectomy. The use of chemotherapy was associated
in a nonsignificant way with worse outcomes (HR, 1.29;
95% CI, 0.72-2.30; P ¼ not significant), possibly a
reflection of selection bias.
Recurrence and Repeat Resection
Among patients undergoing complete resection, recur-
rence of pulmonary metastasis was very common, generally
within 2 years (Figure 2, A). Of 42 patients alive at the end
of the study period, disease status could be documented for
28, 14 of whom (50%) were disease free. Among 76
patients who died, disease status could be documented in
60; all of those patients had recurrent disease at the time
of death, 22 in pulmonary, 14 in extrapulmonary, and 24
in both pulmonary and extrapulmonary locations.
A second complete resection was possible in 32 of 91
initial recurrences, cancer recurred again in 63% of those
patients, another 60% of whomwent on to a third resection.
Given the 83% 5-year recurrence rate, it was important to
understand the implication of recurrence for long-term
survival. Previous studies exploring the predictive value
of either recurrence or repeat resection for survival have
at times been hampered by the bias introduced by the fact
that patients experiencing the earliest deaths have less
time to achieve recurrence. As a result, some authors
have reported recurrence and repeat resection to be
predictors of better survival compared with patients without
recurrence.13,22 To account for this misleading association,
we assessed survival after a first repeat resection, and foundgery c April 2014
FIGURE 3. A, Overall survival in patients who underwent initial
metastasectomy in either the study’s early period (1996-2002)
(blue, n ¼ 39) or late period (2003-2009) (black, n ¼ 79). B, Overall
survival in patients who underwent initial metastasectomy via VATS
(black, n ¼ 44) or open surgery (blue, n ¼ 67). VATS, Video-assisted
thoracic surgery.
FIGURE 2. A, Freedom from recurrence of pulmonary metastasis after
initial metastasectomy. B, Overall survival from the time of repeat
metastasectomy in patients undergoing resection of recurrent pulmonary
metastasis (n ¼ 32).
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respectively) were no worse than after initial metastasec-
tomy (Figure 1, A and Figure 2, B). Cox proportional haz-
ards modeling, however, indicated that a longer time to
recurrence was a likely predictor of better survival after
repeat resection (HR, 0.33; 95% CI, 0.10-1.06; P ¼ .06).
Evolution of Therapeutic Approach
Beginning in 2003, our practice began a shift toward an
increasingly aggressive approach. This shift is reflected in
a difference between time periods with regard to a greater
mean number of lesions (4.8  5.0 vs 2.1  1.4;
P ¼ .003), a greater percentage of patients with>5 lesions
(33% vs 15%; P ¼ .04), a smaller mean lesion diameter
(2.9 3.2 cm vs 5.8 4.8 cm; P<.0001), and a greater per-
centage of patients with lesions of only 1 cm diameter or
less (27% vs 8%; P ¼ .02). The percentages of bilateral
and multilobe disease also increased from 20.5% to
51.9% (P ¼ .001) and from 43.6% to 70.9% (P ¼ .004),
respectively. Furthermore, median DFI was 41.6 months
in the early cohort, but only 25.8 months among the late
cohort (P ¼ .04), reflecting a patient population that wouldThe Journal of Thoracic and Carhave been considered at higher risk by previously published
criteria. The time between identification of pulmonary
metastasis and initial metastasectomy, however, was no
different in the early and late time periods (median interval,
104 [interquartile range, 50-262] and 127 [interquartile
range, 41-281] days, respectively; P ¼ not significant).
Despite this liberalization, survival in the later period was
not statistically different from that in the earlier period
(Figure 3, A) (HR, 1.3; 95% CI, 0.77-2.2; P ¼ .32).
In addition to a more aggressive surgical approach, the
use of VATS increased over time, going from 18% to
47% of cases (P ¼ .002); no difference was observed in
the rate of R1/R2 resections among VATS or open surgery
patients (13% vs 22%; P ¼ not significant). In particular,
a technique was developed by which nearly all of the lung
parenchyma could be brought into contact with the
surgeon’s finger(s) introduced through 1 of the VATS
incisions, allowing digital or bidigital palpation. This
technique enabled identification of lesions as small as 1
mm in diameter, and as this technique evolved there
was no difference in the mean number of lesions resecteddiovascular Surgery c Volume 147, Number 4 1197
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Mann-Whitney U test). There did not appear to be a strong
selection bias favoring VATS patients, because 26% of
VATS cases and 18% of open cases involved resection of
>5 lesions (P ¼ not significant), and although there was
no significant difference between the mean number of small
lesions (<1 cm diameter) resected per patient among VATS
and open thoracotomy patients (2.3  2.8 vs 1.8  2.9,
respectively; P ¼ not significant), the percentage of cases
involving only subcentimeter lesions was higher for VATS
than for open cases (35% vs 19%; P ¼ .04). In addition,
a trend was observed toward more VATS patients having
bilateral disease (48% vs 31%; P ¼ .08), and there was
no statistically significant difference between multilobe
involvement (VATS 67% vs open surgery 54%; P ¼ not
significant). Importantly, no difference was observed in
survival between VATS and open cases (Figure 3, B), nor
was there a difference in time to recurrence of pulmonary
metastasis or the rate of unresectable pulmonary recurrence.
On the other hand, among patients deemed to have a
potentially resectable pulmonary recurrence by their
surgeon, a trend was seen toward more repeat resections
in patients who had originally undergone VATS (100% vs
79%; P ¼ .11), and repeat resection was more likely if
the initial metastasectomy had involved wedge resection
versus anatomic resection (97% vs 50%; P ¼ .01).
DISCUSSION
Pulmonarymetastasectomy is increasingly invoked for an
array of primary cancers, but may have a particularly
important role in the management of metastatic
sarcoma.2,7,8,13,17,23 The propensity of sarcoma to spread
to the lung before other sites, combined with a young and
often otherwise healthy patient population, has created a
strong rationale for its use as a modality that may prolong
life, improve the quality of life and possibly even achieve
long-term cure. Although level I evidence of a survival
benefit with pulmonary metastasectomy is not available
from prospective randomized studies and has therefore
been questioned by some authors,24 the 5- and 10-year
survival data presented here suggest a possible real improve-
ment compared with 25% to 34% 5-year survival reported
in a recent meta-analysis of metastasectomies, and the
13% to 25% survival among sarcoma metastasis in a large
registry.25 It is therefore important for surgeons to under-
stand parameters by which they push the limits of surgical
candidacy, and that patients and surgeons best understand
the implications of clinical risk factors that influence
survival. Although limited by its retrospective nature, our
study provides additional information that reflects modern
diagnostic and therapeutic surgical practice.
Early series examining sarcoma metastasectomy pointed
toward DFI and the number of lesions as predictors
of survival.9,12,26,27 Neither of these variables achieved1198 The Journal of Thoracic and Cardiovascular Surstatistical significance in our univariate or multivariate
analyses. However, 2 related indices that may represent
extreme cases of the pace of global disease and the extent
of local involvement (ie, synchronous metastasis and
pulmonary involvement requiring anatomic resection) did
prove to be independent predictors of increased mortality.
It may be that more aggressive and more successful
surgical approaches have, over time, diminished the
influence of less extreme manifestations of these clinical
phenomena on survival. If sarcoma’s tropism for the lung
is in fact an important impetus for aggressive pulmonary
metastasectomy, the occurrence of extra-pulmonary
metastasis in our cohort was an ominous indicator of rapid
postoperative mortality.
Eighty percent of patients undergoing complete
pulmonary metastasectomy experienced fairly rapid
recurrence, and yet 5-year and 10-year survival was
estimated at a very reasonable 42% and 32%, respectively.
The total number of resections and the number of lesions
did not correlate with outcome, and survival after resection
of a recurrence of pulmonary metastasis was no worse than
survival after resection of the initial metastasis.
The limitations of our study include those of any
retrospective analysis of a relatively rare disease with
limited sample size. A limited number of events influences
multiple predictor models, and we therefore took a
conservative approach to constructing those models guided
heavily by the clinical relevance of possible associations.
In addition, sarcomas represent diverse histologic and
biologic entities, but sample size forced us to consider these
entities as a single group. Although we did not observe any
statistically or clinically significant differences among these
histologic subgroups (with the exception of an increase in
mortality in a small subset of 5 patients with Ewing’s/small
blue cell sarcomas), future, larger cohorts may allow truly
important distinctions to be made.
Another limitation of our study is the absence of
randomization with regard to the use of adjuvant treatments,
as well as incomplete record of the responses of patients to
the regimens used. Although patients with metastatic
sarcoma often received systemic chemotherapy, the
confounding element of treatment bias precludes any
meaningful conclusions regarding efficacy. The type of
chemotherapy employed depended heavily on the subtype
of sarcoma, with doxorubicin and ifosfamide being the
most common regimen for most histologic subtypes.
When recalcitrant recurrence was encountered, other
regimens, such as gemcitabine with or without docetaxel,
or even trabectadin, were attempted, sometimes with a
partial, time-limited response. At this time, the use of
chemotherapy as an adjuvant to metastasectomy is
evaluated on a case-by-case basis at our institution, with a
history of multiple recurrences or very widespread small
lesions often swaying the decision toward either an adjuvantgery c April 2014
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at times used as markers to gauge the response to certain
agents; in such cases, almost inevitable residual disease is
ultimately a target for metastasectomy.
Our institution’s move toward a more aggressive clinical
strategy was not associated with a substantial diminishment
in the utility of the resections, although a nonsignificant shift
of the late survival curvewas observed in more recent years.
In assessing the results of a more aggressive approach, the
potential confounding influence of lead time bias on postop-
erative survival must be considered. In our study the interval
between diagnosis of metastasis and initial metastasectomy
was no shorter during the later, more aggressive time period,
so that the smaller sizes of lesions did not simply reflect
earlier intervention. Furthermore, the increased number
and more diffuse distribution of pulmonary nodules seen
in the later period suggests surgery for more aggressive,
but not necessarily earlier, metastatic disease.
Our successful movement toward more extensive use of
VATS may facilitate a more aggressive reoperative strategy.
Previous studies have emphasized the need for intraoperative
palpation of lung tissue.28,29 Particularly important in our
practice has been the development of a VATS technique
that allows digital palpation of nearly the entire lung. An
ongoing study in our group is now comparing the technical
efficacy of this approach to conventional open thoracotomy.
We have also collaborated in recent years to develop
multidisciplinary strategies toward the clinical goal of
controlling metastatic sarcoma and its recurrence. In addi-
tion to participating in pharmaceutical trials with emerging
sarcoma agents, we have worked closely with colleagues in
radiation oncology to define parameters for the use of
ablative and stereotactic radiation therapies. Although the
high doses of radiation that have become possible with
stereotactic delivery may overcome the traditional radiore-
sistance of many of these tumors, total radiation doses to
normal tissues can become prohibitivewhen numerous met-
astatic lesions need to be addressed. Most often, stereotactic
radiation has been reserved for single or oligo-recurrences
to help obviate the need for potentially morbid reoperation.
As targeted agents continue to be evaluated that may finally
address the unmet need for effective systemic therapy for
this group of diseases, multispecialty sarcoma centers will
increasingly need to implement a sophisticated surgical
approach so that a substantial improvement in the outlook
for these patients can finally be achieved.
The authors thank Ian Wolff for his contribution to the
tabulation and analysis of data.References
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Dr Kenneth Kesler (Indianapolis, Ind). Your finding that
disease-free interval and number of lesions removed does not
negatively influence survival challenges conventional wisdom
and further justifies an aggressive surgical approach, which is
becoming common practice at many institutions. Additionally,
your message that, at the end of the day, survival is probably
more a matter of adverse biology—such as the presence of
synchronous pulmonary or extrapulmonary metastases—than the
approach by which pulmonary metastases are removed, makes
sense. But I also agree with your conclusion that due to the diverse
nature of these cases analysis of larger cohorts are needed to
provide clearer distinctions.
Whereas your finding of no overall survival difference between
patients undergoing video-assisted thoracic surgery (VATS) or an
open approach is of interest, one might expect selection bias; for
example, with open surgery being performed more frequently in
higher risk subsets, such as patients with small, subcentimeter
lesions or patients with >5 lesions, both categories of which
represented approximately one-third of your series. Regardless
of any bias being present or not, providing more detailed
tumor characteristics between the 2 groups and considering
propensity-matched or risk-adjusted survival analysis using
these types of variables might be a better comparison of the
2 approaches. These types of analyses would also make a stronger
argument for the efficacy of VATS if no survival difference is
confirmed.
Twenty-seven patients were not included in your analysis.
Presumably most or all of those patients had incomplete initial
resection with poorer outcomes. Perhaps this is a matter for
another study, but did you analyze this subset with respect to tumor
characteristics and/or surgical approach? For example, it would be
important if a determination could be made regarding which
patients would not likely achieve an R0 resection and thereby
avoid futile surgery.
If a minimally invasive approach resulted in an incomplete
resection that might have been prevented with an open
approach, this could be another important issue. Do you have
any information on this group that might be helpful to guide us
with future surgical management?
Dr Reza. In terms of incomplete resection, the interval to
recurrence after VATS or open surgery was not found to be
different. I think it may be reasonable to postulate that achieving
complete resection was at least similar in both the VATS and
open surgery groups.
We have not looked at the outcomes for patients who underwent
incomplete resections. We believe that the literature has fairly
definitively indicated that those outcomes are worse overall. In
our case, these were not failed attempts at complete resection,
but largely patients who needed either a diagnostic procedure or1200 The Journal of Thoracic and Cardiovascular Surpalliation of a specific complication of a single lesion or subset
of lesions. Our program does offer palliation to patients for
whom it is believed a meaningful difference in quality of life
can be achieved at a reasonable cost of morbidity related to
surgery, but the real goal of our aggressive approach to meta-
stasectomy is improving longer-term outcomes.
Dr Kesler. A number of publications have emphasized
the importance of bimanual palpation of the collapsed lung to
occasionally identify CT occult disease. You mention total lung
palpation during VATS metastasectomy. Would you please
comment further on this technique? Along those same lines, did
you use any localizing procedures preoperatively for smaller,
deeper lesions in patients undergoing a VATS approach?
Dr Reza. The VATS approach that has been used more recently
at our institution allows for more complete palpation of the lung,
largely owing to the port placement of VATS incisions, so that
nearly the entire collapsed lung can be brought closer to the
surgeon’s finger, allowing further palpation or even bidigital
palpation between 2 fingers if not bimanual palpation. We looked
at the ability to detect lesions<5 mm intraoperatively, as well as
being able to detect radiographically occult disease. We found
that the rates were comparable between the VATS and open groups
in identifying lesions<5mm and also radiographically determined
occult disease intraoperatively. In those patients, we have been
able to observe that there may be no limit to the size or number
of lesions that can be successfully approached through VATS,
even compared with open thoracotomy. We are preparing these
observations for presentation elsewhere, but the decision
regarding VATS may be more related to the anatomic location of
certain lesions rather than their number or size. Additionally, we
did not utilize any localizing procedures preoperatively to identify
the metastases. We have found that even very deep lesions can
often be palpated through the collapsed lung, and with proper
placement of incisions the lung can be brought close enough to
the surgeon’s finger to enable such palpation via VATS.
Dr Kesler. Did any patient undergoing open metastasectomy in
your series have an unexpected finding at the time of surgery that
might not have been identified during a VATS approach, such as an
occult lung, peribronchial lymph node, or small pleural
metastasis?
Dr Reza. There were certainly many patients who had CT
occult lymph nodes or nodules in both the open and VATS groups
that were discovered at surgery and resected. Our VATS technique
does enable discovery of these CT occult lesions. Resections of
benign nodules were not counted as positive resections and are
therefore not reflected in the data I presented today.
Dr Kesler. Apparently the use of chemotherapy was not a
predictive variable in your series. Would you please share your
current strategy with respect to the use of chemotherapy in these
patients? As a corollary, if you are using chemotherapy mainly
in the neoadjuvant setting, have you investigated the response of
chemotherapy as it relates to survival?
Dr Reza. We did not observe any relationship between the use
of chemotherapy and survival, whether the chemotherapy was
related to the metastasis or treatment of the primary tumor.
Chemotherapy is sometimes recommended to our patients
before metastasectomy, largely based on an individual patient’s
larger clinical context. Rapidly recurrent metastasis after initialgery c April 2014
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Sresection, for example, or a perception of extensive disease that
may not be amenable to complete resection, or the involvement
of numerous small nodules that suggest a tip of the iceberg
situation may all be scenarios in which a patient might be more
likely to receive systemic therapy. The type of sarcoma, its rate
of growth, and its likelihood to respond to available regimens
also plays a role in this decision. We have not yet systematically
analyzed the results of chemotherapy use in our patients with
sarcoma; we have never randomized patients to chemotherapy,
so that analysis will be statistically very challenging. In terms of
final recommendations on a specific strategy, I cannot comment
on what those are.
Dr Daniel L. Miller (Atlanta, Ga). I enjoyed your presentation.
I think more and more of us are doing more VATS procedures for
metastatic disease.
I have just 1 comment and 1 question. About 7 to 5 days before
surgery, we will go over with a radiologist the areas that we are
going after, and he or she will list out what slice that nodule is
on and so forth. It is a great planning exercise. So when we get
in the operating room, we know that there are 3 in the upper
lobe, 2 in the middle, and so forth. I think that has really helped
us, because sometimes you come back at 4 months with another
CT scan and there will be 1 little guy that you didn’t get.
Were the lobectomies is your experiences related to central
disease or for multiple nodules? A lot of times, if a patient has
4 or 5 nodules—usually in the lower lobe because of perfusion
and so forth—then I will do a lobectomy, which is very easy
thoracoscopically, especially if they don’t have a lot of disease
on the other side. Please comment on the reason for the lobectomy.The Journal of Thoracic and CarDrReza.Many of the lobectomies were required because of the
position of the tumor, because wedging it out without taking the
lobe would have been difficult. The lobe was taken in those cases.
There are likely a few cases where patients had diffuse metastatic
disease in whom it made more sense to take the lobe, although I do
not know the exact number of cases for which this was the
situation.
Dr Miller. Also, for our really deep lesions, we will do a
fiducial, which will be placed by a member of the radiology
team, and then wewill do fluoroscopic guidance. That really helps.
You minimize the amount of lung that you take.
DrMarcelo Cypel (Toronto, Ontario, Canada). I think 1 of the
main end points we should be looking at in comparisons between
VATS and thoracotomy is the incidence of ipsilateral recurrence.
Have you looked at that specifically in these 2 groups?
Dr Reza. We did not specifically analyze for ipsilateral
recurrence, although the overall recurrence rates were very similar
between VATS and open surgery.
Dr Cypel. I think that will tell if you left some lesions behind in
your VATS approach or not.
Dr Walter J. Scott (Philadelphia, Pa). Would you please
describe for us your criteria for considering someone
unresectable?
Dr Reza. The designation of unresectable was determined by
the treating surgeon, generally based on the extent of the patient’s
pulmonary disease but also considering other factors, such
as extensive extrapulmonary disease. In our series, 32 out of
36 patients with resectable disease underwent resection. However,
there were no predetermined or established criteria used.diovascular Surgery c Volume 147, Number 4 1201
